摘要
目的分析吡格列酮联合阿卡波糖治疗老年2型糖尿病对血糖水平的改善效果。方法选取2021年2月—2022年2月龙岩人民医院心血管内科收治的76例老年2型糖尿病患者,随机分为研究组与对比组,每组38例。对比组采用阿卡波糖治疗,研究组采用吡格列酮联合阿卡波糖治疗,观察两组治疗前后的血糖水平、胰岛素功能以及不良反应发生率。结果治疗前,两组患者的血糖水平和胰岛素功能指标比较,差异无统计学意义(P>0.05);治疗后,两组患者的血糖水平和胰岛素功能指标均得到改善,研究组血糖水平、胰岛素抵抗指数、胰岛素敏感指数均低于对比组,胰岛素分泌指数高于对比组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论吡格列酮联合阿卡波糖治疗老年2型糖尿病对血糖水平的改善效果令人满意,通过促进胰岛素分泌,使胰岛素抵抗下降,显著降低血糖,同时不增加不良反应出现风险。
Objective To analyze the effect of pioglitazone combined with acarbose on the improvement of blood glucose level in the treatment of type 2 diabetes in the elderly.Methods Seventy-six elderly patients with type 2 diabetes mellitus admitted to the Department of Cardiovascular Medicine,Longyan People’s Hospital from February 2021 to February 2022 were included in the study and randomly divided into a study group and a comparison group,with 38cases in each group.The comparison group was treated with acarbose and the study group was treated with pioglitazone combined with acarbose,and the blood glucose level,insulin function and the probability of adverse reactions in the two groups before and after treatment were observed.Results Before treatment,there was no statistically significant difference in the blood glucose level and insulin function index between the two groups(P>0.05);after treatment,the blood glucose level and insulin function indexes of both groups were improved,and the blood glucose level the insulin resistance index and insulin sensitivity index of the study group were lower than that of the comparison group,and the insulin secretion index was higher than that of the comparison group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The effect of pioglitazone combined with acarbose on the improvement of blood glucose level in the treatment of type 2 diabetes in the elderly is satisfactory,and by promoting insulin secretion and decreasing insulin resistance,it significantly reduces blood glucose without increasing the risk of adverse effects.
作者
林白燕
习贵新
黄荣国
陈旭
LIN Baiyan;XI Guixin;HUANG Rongguo;CHEN Xu(Department of Cardiovascular Medicine,Longyan People's Hospital,Longyan,Fujian Province,364000 China)
出处
《糖尿病新世界》
2022年第23期96-98,102,共4页
Diabetes New World Magazine
关键词
吡格列酮
阿卡波糖
老年2型糖尿病
胰岛素功能
Pioglitazone
Acarbose
Geriatric type 2 diabetes mellitus
Insulin function
作者简介
林白燕(1990-),女,本科,住院医师,主要从事心血管内科临床工作。
